Core Viewpoint - The announcement highlights a significant licensing agreement between Jiangsu Xiansheng Zaiming Pharmaceutical Co., Ltd. and Ipsen Pharma SAS, granting Ipsen exclusive global rights to develop, manufacture, and commercialize the antibody-drug conjugate SIM0613 outside Greater China, with potential financial benefits for the company totaling up to $1.06 billion [1]. Group 1: Licensing Agreement Details - Jiangsu Xiansheng has signed an exclusive licensing agreement with Ipsen for the ADC SIM0613, targeting LRRC15 [1]. - Ipsen will pay an upfront fee of $45 million, along with milestone payments related to research, regulatory, and commercialization achievements, and tiered royalties on sales [1]. Group 2: Product Information - SIM0613 is a novel ADC that targets LRRC15, a protein highly expressed on the surface of various solid tumors and cancer-associated fibroblasts, but minimally expressed in normal cells [1]. - The design of SIM0613 allows it to penetrate tumors and cancer-associated fibroblasts effectively, demonstrating significant tumor regression in various preclinical in vivo models [1].
先声药业(02096)附属与Ipsen就SIM0613(LRRC15抗体偶联药物)签订独家授权许可协议